Hadasit portfolio co receives approval for colon cancer test

Biomarker Technologies has also received a loan to complete its breast cancer testing trial.

Hadasit Bio Holdings Ltd. (TASE:HDST) portfolio company Biomarker Technologies Ltd. has received Hadassah Medical Organization's ethics committee approval to begin a clinical trial for the early detection of colon cancer. Using routine blood testing procedures, the trial will investigate a large number of blood samples, in collaboration with Hadassah Ein Kerem Medical Center's oncology department, to test the effectiveness of the company's early diagnosis method for colon cancer.

Hadasit Bio also announced that it is extending a NIS 1.2 million convertible loan to Biomarker to complete its previous clinical trial, to identify and monitor breast cancer through blood tests, and to fund this latest colon cancer testing trial.

Biomarker develops molecular diagnostic tools based on innovative biomarkers to detect early stage cancer through routine blood tests. Hadasit hold 87.5% of Biomarker.

Hadasit's Bio's share price rose 1.13% in afternoon trading to NIS 0.98.

Published by Globes, Israel business news - www.globes-online.com - on March 6, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס